UroGen Pharma Ltd. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
UroGen Pharma Ltd. (URGN) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$10.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$10.00K.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$11.00K.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$4.00K.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $17.00K, a 93.63% decline year-over-year.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$37.00K, a 184.09% decline from fiscal 2024.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $44.00K, a 63.03% decline from fiscal 2023.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $119.00K.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$82.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$10.00K 10-Q · filed 2026-08-05 | -$21.00K 10-Q · filed 2026-08-05 | -$25.00K derived: sum of 3 quarters · filed 2026-08-05 | -$8.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$11.00K 10-Q · filed 2026-05-06 | -$15.00K derived: sum of 2 quarters · filed 2026-05-06 | $2.00K derived: sum of 3 quarters · filed 2026-05-06 | -$6.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.00K derived: sum of 2 quarters · filed 2026-03-02 | $5.00K derived: sum of 3 quarters · filed 2026-08-05 | -$37.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $17.00K 10-Q · filed 2025-11-06 | $9.00K derived: sum of 2 quarters · filed 2026-08-05 | -$33.00K 10-Q · filed 2025-11-06 | -$213.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$8.00K 10-Q · filed 2026-08-05 | -$50.00K 10-Q · filed 2026-08-05 | -$230.00K derived: sum of 3 quarters · filed 2026-08-05 | $37.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$42.00K 10-Q · filed 2026-05-06 | -$222.00K derived: sum of 2 quarters · filed 2026-05-06 | $45.00K derived: sum of 3 quarters · filed 2026-05-06 | $51.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $87.00K derived: sum of 2 quarters · filed 2026-03-02 | $93.00K derived: sum of 3 quarters · filed 2026-03-02 | $44.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | $267.00K 10-Q · filed 2025-11-06 | $273.00K derived: sum of 2 quarters · filed 2025-11-06 | $224.00K 10-Q · filed 2025-11-06 | $370.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $6.00K 10-Q · filed 2025-08-07 | -$43.00K 10-Q · filed 2025-08-07 | $103.00K derived: sum of 3 quarters · filed 2025-08-07 | $123.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$49.00K 10-Q · filed 2025-05-12 | $97.00K derived: sum of 2 quarters · filed 2025-05-12 | $117.00K derived: sum of 3 quarters · filed 2025-05-12 | $8.00K derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $166.00K derived: sum of 2 quarters · filed 2025-03-10 | $57.00K derived: sum of 3 quarters · filed 2025-03-10 | $119.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $20.00K 10-Q · filed 2024-11-06 | -$89.00K derived: sum of 2 quarters · filed 2024-11-06 | -$27.00K 10-Q · filed 2024-11-06 | $21.00K derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$109.00K 10-Q · filed 2024-08-13 | -$47.00K 10-Q · filed 2024-08-13 | $1.00K derived: sum of 3 quarters · filed 2024-08-13 | -$98.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $62.00K 10-Q · filed 2024-05-13 | $110.00K derived: sum of 2 quarters · filed 2024-05-13 | $11.00K derived: sum of 3 quarters · filed 2024-05-13 | $24.00K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$51.00K derived: sum of 2 quarters · filed 2024-03-14 | -$38.00K derived: sum of 3 quarters · filed 2024-03-14 | -$82.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | -$99.00K 10-Q · filed 2023-11-14 | -$86.00K derived: sum of 2 quarters · filed 2023-11-14 | -$130.00K 10-Q · filed 2023-11-14 | -$159.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $13.00K 10-Q · filed 2023-08-10 | -$31.00K 10-Q · filed 2023-08-10 | -$60.00K derived: sum of 3 quarters · filed 2023-08-10 | -$101.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$44.00K 10-Q · filed 2023-05-11 | $44.00K 10-Q · filed 2022-05-10 | -$73.00K derived: sum of 2 quarters · filed 2023-05-11 | -$114.00K derived: sum of 3 quarters · filed 2023-05-11 | -$212.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$70.00K derived: sum of 2 quarters · filed 2023-03-24 | -$168.00K derived: sum of 3 quarters · filed 2023-03-24 | -$296.00K 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$41.00K 10-Q · filed 2022-11-10 | -$139.00K derived: sum of 2 quarters · filed 2022-11-10 | -$267.00K 10-Q · filed 2022-11-10 | -$488.00K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$98.00K 10-Q · filed 2022-08-11 | -$226.00K 10-Q · filed 2022-08-11 | -$447.00K derived: sum of 3 quarters · filed 2022-08-11 | -$715.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$128.00K 10-Q · filed 2022-05-10 | -$349.00K derived: sum of 2 quarters · filed 2022-05-10 | -$617.00K derived: sum of 3 quarters · filed 2022-05-10 | ||
| 2020-12-31 | -$221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$489.00K derived: sum of 2 quarters · filed 2022-03-21 | -$5.00K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$268.00K 10-Q · filed 2021-11-15 | $216.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |